Number of Participants With Worst Case Chemistry Results by Maximum Grade Increase Post-baseline Relative to Baseline
Tovorafenib (DAY101) Monotherapy for Patients With Melanoma and Other Solid Tumors · Source last updated 2025-10-02
Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.
Measure
COUNT_OF_PARTICIPANTS
Unit
Participants
Interval / dispersion
Not reported
Time frame
Baseline and up to 23 months
What was measured
Blood samples were collected for the analysis of following chemistry parameters: creatine phosphokinase (CPK) increased, hypokalemia, hypoalbuminemia, hypercalcemia, hypocalcemia and hyponatremia. Grade 1 (G1): mild; Grade 2 (G2): moderate; Grade 3 (G3): severe; Grade 4 (G4) life-threatening or disabling. Higher grade indicates greater severity and an increase in CTCAE grade was defined relative to the Baseline grade. Any worst-case post baseline increase to G2, G3, and G4 are presented. The laboratory parameters were graded according to CTCAE version 5.
Analysis population: Safety Analysis Set comprises of all patients enrolled in the study who receive at least one dose of study drug.
Groups in this outcome
Melanoma Cohort
Adult participants (≥ 18 years) were administered Tovorafenib 600 mg orally (PO) once weekly (QW).
Tissue Agnostic Cohort
Adult participants (≥ 18 years) were administered Tovorafenib 600 mg PO QW.
Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.
Analysis denominator · Participants
Group
Source count
Melanoma Cohort
8
Tissue Agnostic Cohort
15
Reported measurements
CPK increased, Increased to Grade 2
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Melanoma Cohort
2
Not reported
Not reported
Not reported
Not reported
Tissue Agnostic Cohort
4
Not reported
Not reported
Not reported
Not reported
CPK increased, Increased to Grade 3
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Melanoma Cohort
0
Not reported
Not reported
Not reported
Not reported
Tissue Agnostic Cohort
1
Not reported
Not reported
Not reported
Not reported
CPK increased, Increased to Grade 4
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Melanoma Cohort
1
Not reported
Not reported
Not reported
Not reported
Tissue Agnostic Cohort
0
Not reported
Not reported
Not reported
Not reported
Hypoalbuminemia, Increased to Grade 2
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Melanoma Cohort
1
Not reported
Not reported
Not reported
Not reported
Tissue Agnostic Cohort
2
Not reported
Not reported
Not reported
Not reported
Hypoalbuminemia, Increased to Grade 3
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Melanoma Cohort
0
Not reported
Not reported
Not reported
Not reported
Tissue Agnostic Cohort
0
Not reported
Not reported
Not reported
Not reported
Hypoalbuminemia, Increased to Grade 4
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Melanoma Cohort
0
Not reported
Not reported
Not reported
Not reported
Tissue Agnostic Cohort
0
Not reported
Not reported
Not reported
Not reported
Hypokalemia, Increased to Grade 2
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Melanoma Cohort
1
Not reported
Not reported
Not reported
Not reported
Tissue Agnostic Cohort
5
Not reported
Not reported
Not reported
Not reported
Hypokalemia, Increased to Grade 3
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Melanoma Cohort
0
Not reported
Not reported
Not reported
Not reported
Tissue Agnostic Cohort
1
Not reported
Not reported
Not reported
Not reported
Hypokalemia, Increased to Grade 4
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Melanoma Cohort
0
Not reported
Not reported
Not reported
Not reported
Tissue Agnostic Cohort
0
Not reported
Not reported
Not reported
Not reported
Hyponatremia, Increased to Grade 2
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Melanoma Cohort
1
Not reported
Not reported
Not reported
Not reported
Tissue Agnostic Cohort
1
Not reported
Not reported
Not reported
Not reported
Hyponatremia, Increased to Grade 3
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Melanoma Cohort
0
Not reported
Not reported
Not reported
Not reported
Tissue Agnostic Cohort
0
Not reported
Not reported
Not reported
Not reported
Hyponatremia, Increased to Grade 4
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Melanoma Cohort
0
Not reported
Not reported
Not reported
Not reported
Tissue Agnostic Cohort
0
Not reported
Not reported
Not reported
Not reported
Hypercalcemia, Increased to Grade 2
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Melanoma Cohort
0
Not reported
Not reported
Not reported
Not reported
Tissue Agnostic Cohort
0
Not reported
Not reported
Not reported
Not reported
Hypercalcemia, Increased to Grade 3
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Melanoma Cohort
0
Not reported
Not reported
Not reported
Not reported
Tissue Agnostic Cohort
1
Not reported
Not reported
Not reported
Not reported
Hypercalcemia, Increased to Grade 4
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Melanoma Cohort
0
Not reported
Not reported
Not reported
Not reported
Tissue Agnostic Cohort
0
Not reported
Not reported
Not reported
Not reported
Hypocalcemia, Increased to Grade 2
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Melanoma Cohort
0
Not reported
Not reported
Not reported
Not reported
Tissue Agnostic Cohort
1
Not reported
Not reported
Not reported
Not reported
Hypocalcemia, Increased to Grade 3
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Melanoma Cohort
0
Not reported
Not reported
Not reported
Not reported
Tissue Agnostic Cohort
0
Not reported
Not reported
Not reported
Not reported
Hypocalcemia, Increased to Grade 4
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Melanoma Cohort
0
Not reported
Not reported
Not reported
Not reported
Tissue Agnostic Cohort
0
Not reported
Not reported
Not reported
Not reported
Complete source fields
classes
categories
measurements
group Id
OG000
value
2
group Id
OG001
value
4
title
CPK increased, Increased to Grade 2
categories
measurements
group Id
OG000
value
0
group Id
OG001
value
1
title
CPK increased, Increased to Grade 3
categories
measurements
group Id
OG000
value
1
group Id
OG001
value
0
title
CPK increased, Increased to Grade 4
categories
measurements
group Id
OG000
value
1
group Id
OG001
value
2
title
Hypoalbuminemia, Increased to Grade 2
categories
measurements
group Id
OG000
value
0
group Id
OG001
value
0
title
Hypoalbuminemia, Increased to Grade 3
categories
measurements
group Id
OG000
value
0
group Id
OG001
value
0
title
Hypoalbuminemia, Increased to Grade 4
categories
measurements
group Id
OG000
value
1
group Id
OG001
value
5
title
Hypokalemia, Increased to Grade 2
categories
measurements
group Id
OG000
value
0
group Id
OG001
value
1
title
Hypokalemia, Increased to Grade 3
categories
measurements
group Id
OG000
value
0
group Id
OG001
value
0
title
Hypokalemia, Increased to Grade 4
categories
measurements
group Id
OG000
value
1
group Id
OG001
value
1
title
Hyponatremia, Increased to Grade 2
categories
measurements
group Id
OG000
value
0
group Id
OG001
value
0
title
Hyponatremia, Increased to Grade 3
categories
measurements
group Id
OG000
value
0
group Id
OG001
value
0
title
Hyponatremia, Increased to Grade 4
denoms
counts
group Id
OG000
value
8
group Id
OG001
value
15
units
Participants
description
Blood samples were collected for the analysis of following chemistry parameters: creatine phosphokinase (CPK) increased, hypokalemia, hypoalbuminemia, hypercalcemia, hypocalcemia and hyponatremia. Grade 1 (G1): mild; Grade 2 (G2): moderate; Grade 3 (G3): severe; Grade 4 (G4) life-threatening or disabling. Higher grade indicates greater severity and an increase in CTCAE grade was defined relative to the Baseline grade. Any worst-case post baseline increase to G2, G3, and G4 are presented. The laboratory parameters were graded according to CTCAE version 5.
groups
description
Adult participants (≥ 18 years) were administered Tovorafenib 600 mg orally (PO) once weekly (QW).
id
OG000
title
Melanoma Cohort
description
Adult participants (≥ 18 years) were administered Tovorafenib 600 mg PO QW.
id
OG001
title
Tissue Agnostic Cohort
param Type
COUNT_OF_PARTICIPANTS
population Description
Safety Analysis Set comprises of all patients enrolled in the study who receive at least one dose of study drug.
reporting Status
POSTED
time Frame
Baseline and up to 23 months
title
Number of Participants With Worst Case Chemistry Results by Maximum Grade Increase Post-baseline Relative to Baseline